- Biologos has appointed Hetal Patel as Chief Executive Officer as the company marks its 50th anniversary.
- The appointment follows recent investments in facilities and capabilities to support customers in biopharma, cell and gene therapy, tissue processing, and animal health markets.
Biologos has appointed Hetal Patel as Chief Executive Officer, coinciding with the company’s 50th anniversary and recent investments in manufacturing capacity and operational capabilities. The company produces sterile-filtered liquid solutions used in biopharma, cell and gene therapy (CGT), tissue processing, and animal health applications.
Founded in 1976, Biologos manufactures sterile-filtered buffers, media, sera, and reagents for life sciences customers. The company initially focused on the animal health market before expanding into tissue processing in 2012 and entering biopharma and CGT markets in 2021. In 2024, the business was acquired by Ampersand Capital Partners.
“Biologos has an exceptional legacy built on integrity, agility, and an unwavering commitment to customers.”
Hetal Patel, Chief Executive Officer of Biologos
The company operates from a 32,000-square-foot ISO 13485-certified and GMP-compliant manufacturing facility in Glendale Heights, Illinois. The facility was designed to expand manufacturing capacity and support reliable production for customers requiring sterile-filtered liquid solutions.
According to the company, Biologos maintains a 98% customer retention rate and has expanded its operational footprint with centrally located fulfillment hubs. The investments are intended to support customers with customized products and just-in-time inventory management while maintaining compliance with GMP standards.
